No significant grade 3 + or 4 + ARD differences were observed for pathological type, histopathological grade, tumor stage, ER, PR, HER2, triple-negative breast cancer (TNBC), neoadjuvant chemotherapy, surgery, adjuvant chemotherapy, and anti HER2 targeted therapy. Here, ESR1 is linked to triple-negative breast carcinoma.